Cantor downgraded Jazz Pharmaceuticals (NASDAQ:JAZZ) to neutral from overweight, citing the company’s increasing focus on oncology rather than sleep and epilepsy.

Calling the move a “head scratcher,” Cantor pointed out that most of the company’s revenue and growth continue to emanate from